PMID- 9700950
OWN - NLM
STAT- MEDLINE
DCOM- 19981020
LR  - 20190905
IS  - 0885-3177 (Print)
IS  - 0885-3177 (Linking)
VI  - 17
IP  - 2
DP  - 1998 Aug
TI  - Acute postprandial gastrointestinal and metabolic effects of wheat amylase 
      inhibitor (WAI) in normal, obese, and diabetic humans.
PG  - 176-81
AB  - Amylase inhibition has gastrointestinal and metabolic effects that may aid in the 
      treatment of diabetes and obesity. We tested whether 4 g of a commercially 
      available wheat amylase inhibitor (WAI) affected postprandial carbohydrate (CHO) 
      absorption and plasma glucose or hormones. Twelve persons (four lean and four 
      obese nondiabetics and four obese type II diabetics) were studied on 2 separate 
      days. After eating a weight maintenance diet (55% CHO, 20% protein, and 25% fat, 
      as percentage of calories) for 3 days, subjects ate a breakfast containing 650 
      kcal, the same proportion of nutrients as calories, and in random order, either 
      WAI or no WAI. Breath H2 and plasma glucose and hormones were measured every 15 
      and 30 min, respectively, for 7 h. WAI decreased the delta peak postprandial 
      plasma glucose concentrations in 10 of 12 subjects (p < 0.05) and increased the 
      breath H2 levels in 11 (p = 0.02); the increases in breath H2 were small, 
      generally <20 ppm. No subject experienced a change in stools, diarrhea, or 
      bloating. In response to WAI, gastric inhibitory peptide decreased (p < 0.05), 
      peptide YY increased (p < 0.05), and there was a trend toward increased human 
      pancreatic polypeptide (p = 0.07). Although WAI delays CHO absorption and reduces 
      peak postprandial plasma glucose concentrations, overall CHO malabsorption is 
      minimal (as reflected by breath hydrogen and hormones) and without symptoms. It, 
      therefore, may be useful in treating type II diabetes mellitus.
FAU - Lankisch, M
AU  - Lankisch M
AD  - Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, 
      Minnesota 55905, USA.
FAU - Layer, P
AU  - Layer P
FAU - Rizza, R A
AU  - Rizza RA
FAU - DiMagno, E P
AU  - DiMagno EP
LA  - eng
GR  - MO1 RR00585/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pancreas
JT  - Pancreas
JID - 8608542
RN  - 0 (Blood Glucose)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Gastrointestinal Hormones)
RN  - 0 (Plant Proteins)
RN  - 0 (WDAI-3 protein, Triticum aestivum)
RN  - EC 3.2.1.1 (alpha-Amylases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/analysis
MH  - Breath Tests
MH  - Carbohydrate Metabolism
MH  - Diabetes Mellitus, Type 2/*metabolism
MH  - Enzyme Inhibitors/*pharmacology
MH  - Female
MH  - Gastrointestinal Hormones/blood
MH  - Humans
MH  - Intestinal Absorption/*drug effects/physiology
MH  - Male
MH  - Middle Aged
MH  - Obesity/*metabolism
MH  - Plant Proteins/*pharmacology
MH  - Postprandial Period
MH  - Triticum
MH  - alpha-Amylases/*antagonists & inhibitors
EDAT- 1998/08/13 00:00
MHDA- 1998/08/13 00:01
CRDT- 1998/08/13 00:00
PHST- 1998/08/13 00:00 [pubmed]
PHST- 1998/08/13 00:01 [medline]
PHST- 1998/08/13 00:00 [entrez]
AID - 10.1097/00006676-199808000-00011 [doi]
PST - ppublish
SO  - Pancreas. 1998 Aug;17(2):176-81. doi: 10.1097/00006676-199808000-00011.